AAVantgard bio s.r.l.
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
Our platforms (dual hybrid and intein-mediated) are being validated in two inherited retinal diseases (IRDs) with a high unmet need: Usher syndrome type 1B (USH1B) and Stargardt disease (STGD) respectively and have the potential to be extended into different diseases caused by a mutated large gene.
